Join the premier metrology and quality assurance event of the year

ZEISS QUALITY INNOVATION SUMMIT in Berlin, October 22-24, 2024.

Anna Törner: ”Orphan Designation – the "petite robe noire" of drug development”

It is easy to cling to various regulatory incentives, like orphan designation, and other expedited pathways, without understanding what they truly mean or wheth...

From Valneva to the CEO position at NorthX – “I saw it as a great opportunity”

A new cell therapy for leukaemia, a vaccine in tablet form against cholera, and a proprietary mRNA line with the potential capacity to supply the entire Nordic ...

It couldn’t be simpler

AI-assisted ZEISS Solution inspects implant coatings automatically.

HAB Nicolai Johannsen

Fast Optical Sectioning of Developing Organisms and Tissue Microstructures

ZEISS Lattice SIM 3 exploits the full potential of the SIM Apotome technology.

Learn from Speakers from Leading MedTech Companies

Watch the recordings from ZEISS Quality Innovation Days whenever it suits you.

“Don’t postpone the transition to IVDR”

Operators who have not yet started to adapt to the requirements of the new EU IVDR regulation are running out of excuses. This is the opinion of Helena Dzojic, ...

FDA godkänner Gileads injektion mot hiv: ”Avgörande ögonblick”

Gilead Sciences förbyggande hiv-läkemedel lenakapavir godkändes på onsdagen av den amerikanska läkemedelsmyndigheten FDA. Nu tänds hoppet om att äntligen kunna ...

One last chance to register for the premier metrology event in 2024

ZEISS QUALITY INNOVATION SUMMIT.

Behöver du vätskekylning under noll grader?

SMC erbjuder cirkulationskylare för en rad olika appikationer och temperaturer, minusgrader inkluderat. Kontakta oss så hittar vi rätt lösning för dig!

Integrated solutions for liquid handling

Greater efficiency for manufacturers in laboratory automation and many other industries

ZEISS receives FDA clearance for INTRABEAM 700

With its new treatment platform for intraoperative radiotherapy, ZEISS is actively shaping the medical innovation of neuro tumor therapy.

How to optimise your liquid handling results

In dispensing or pipetting applications in laboratory automation, it is important to obtain reliable results, which are analysed by calculating the accuracy and...

”Information security must become part of the Swedish life science strategy”

Sweden needs knowledge security to stand strong in the global competition, writes Björn Ursing in an opinion article.

Her company is developing a new tablet form obesity drug

Obesity and diabetes are the primary targets of a new tablet treatment under development by Malmö-based Pila Pharma. The company’s ambition is to take on the bi...

Obesity-drug pioneers win Lasker Award

This year’s Lasker Prize in Clinical Research has been awarded to three researchers for their discoveries in GLP-1-based drugs that, according to the jury, “hav...

Medeon AB

Level up your medical expertise

Learn from innovative industry speakers from leading MedTech companies at ZEISS Quality Innovation Days.

Dödsstraff yrkas för mordet på amerikansk vård-vd

Åklagarsidan kommer att yrka på dödsstraff för Luigi Mangione, som står inför rätta för mordet på sjukvårdsförsäkringsbolaget United Healths vd Brian Thompson i New York i fjol....

Trends and overview: ELRIG "Robotics and Automation"

Laboratories on the way to end-to-end automation: Robotics, artificial intelligence and automation technology boosted by pandemic

Total pipeline of pharmaceutical companies reaches a record high – 22,921 medicines are currently being developed

Despite the difficult economic times, pharmaceutical companies have never developed as many new drugs as now.

Alvotech i nytt miljardavtal om biosimilarer

Stockholmsnoterade Alvotech har ingått avtal med brittiska Advanz Pharma om kommersialisering av tre biosimilarkandidater.

Business Sweden: “Companies have a lot to offer in data-driven precision medicine”

Data-driven precision medicine can potentially solve major healthcare problems, states Business Sweden in a new report on the subject.